Categories
Health

Johnson & Johnson’s Vaccine Provides Sturdy Safety however Fuels Concern About Variants

[Live updates: follow our coverage of the coronavirus]

Johnson & Johnson announced on Friday that its one-dose coronavirus vaccine provided strong protection against Covid-19, potentially offering the United States a third powerful tool in a desperate race against a worldwide rise in virus mutations.

But the results came with a significant cautionary note: The vaccine’s efficacy rate dropped from 72 percent in the United States to 57 percent in South Africa, where a highly contagious variant is driving most cases. Studies suggest that this variant also blunts the effectiveness of Covid vaccines made by Pfizer-BioNTech, Moderna and Novavax. The variant has spread to at least 31 countries, including the United States, where two cases were documented this week.

Johnson & Johnson said that it planned to apply for emergency authorization of the vaccine from the Food and Drug Administration as soon as next week, putting it on track to receive clearance later in February.

“This is the pandemic vaccine that can make a difference with a single dose,” said Dr. Paul Stoffels, the chief scientific officer of Johnson & Johnson.

The Johnson & Johnson vaccine was 85 percent effective in preventing severe disease, regardless of what variant caused it, the company said. While less effective than the Moderna and Pfizer vaccines, Johnson & Johnson’s is still considered a strong vaccine by scientists. Annual flu vaccines, for example, are typically 40 to 60 percent effective.

The company’s announcement comes as the Biden administration is pushing to immunize Americans faster even with a tight vaccine supply. White House officials have been counting on Johnson & Johnson’s vaccine to ease the shortfall. But the company may only have about seven million doses ready when the F.D.A. decides whether to authorize it, according to federal health officials familiar with its production, and about 30 million doses by early April.

The variant from South Africa, known as B.1.351, could make things even worse for the vaccine push. Given the speed at which the variant swept through that country, it is conceivable that by April it could make up a large fraction of infections in the United States.

The fact that four vaccines backed by the federal government seem to be less effective against the B.1.351 variant has unsettled federal officials and vaccine experts alike. Facing this uncertainty, many researchers said it was imperative to get as many people vaccinated as possible — quickly. Lowering the rate of infection could thwart the contagious variants while they are still rare, and prevent other viruses from gaining new mutations that could cause more trouble.

“If ever there was reason to vaccinate as many people as expeditiously as we possibly can with the vaccine that we have right now, now is the time,” Dr. Anthony S. Fauci, the government’s top infectious disease expert, said in an interview. “Because the less people that get infected, the less chance you’re going to give this particular mutant a chance to become dominant.”

As the United States scrambles to get enough vaccines, the country is turning into something of an evolutionary experiment. The B.1.351 variant is one of several that have arrived in the country or originated here, all with the ability to spread faster than other variants.

“The pandemic is a lot more complicated now than it was a couple months ago,” said Dr. Dan Barouch, a virologist at Beth Israel Medical Center in Boston.

Vaughan Cooper, an evolutionary biologist at the University of Pittsburgh, said that all the new variants were likely evolving quietly for months before bursting on the scene. “I think we’re going to see many stories like this,” he said.

Federal regulators are also still waiting on data from Johnson & Johnson’s new manufacturing facility in Baltimore that prove it can mass-produce the vaccine. The company is counting on that factory to help reach its contractual pledge to the federal government of 100 million doses by the end of June.

If Johnson & Johnson can deliver vaccines quickly enough to the United States, it might be able to help drive down cases before variants make things worse. Since the vaccine requires only a single shot — unlike the Moderna and Pfizer-BioNTech vaccines, which require two — that delivery would translate into full coverage for 100 million people.

Johnson & Johnson’s vaccine has another advantage that might help speed up the rollout. It can stay viable in a refrigerator for three months, while the two authorized vaccines have to be kept frozen. That gives the company an edge not just in reaching more isolated parts of the United States, but in getting the vaccine to remote areas of the world that could otherwise seed more aggressive mutants.

“I hope this vaccine gets approved as soon as possible to reduce disease burden around the world,” said Akiko Iwasaki, immunologist at Yale University. She pointed out that the shot greatly reduced the number of severe Covid cases, even those caused by the variant. “This is a really great result.”

Still, Johnson & Johnson and other vaccine makers must prepare for the B.1.351 variant or another one surging to dominance and demanding new vaccines. “You’ve got to be nimble enough to be able to adapt by upgrading our vaccines that match the dominant strain,” Dr. Fauci said.

Exactly when to make that switch will be a difficult decision, because the viruses are spreading unpredictably, and manufacturing new doses will be a huge undertaking.

“The implications of that are big. You would not take that choice lightly,” said John D. Grabenstein, an epidemiologist with the Immunization Action Coalition, a nonprofit organization that disseminates information about vaccines. “It’s not doomsday. It’s just that we are going to need a bigger boat.”

Johnson & Johnson’s announcement came one day after Novavax said an early analysis of its 15,000-person trial in Britain had revealed that the two-dose vaccine had an efficacy rate of nearly 90 percent there. But in a small trial in South Africa, the efficacy rate dropped to just under 50 percent.

Johnson & Johnson presented only a summary of findings of its clinical trial. The vaccine was 85 percent effective in preventing severe disease in all three regions where the trial was run: the United States, Latin America and South Africa. After 28 days, none of the vaccinated participants who developed Covid-19 had to be hospitalized.

The company reported that the vaccine’s protective effect seems to increase with time. But without long-term data on immunity, scientists and regulators do not yet know whether the vaccine’s efficacy peaks at some point before dropping.

Covid-19 Vaccines ›

Answers to Your Vaccine Questions

Am I eligible for the Covid vaccine in my state?

Currently more than 150 million people — almost half the population — are eligible to be vaccinated. But each state makes the final decision about who goes first. The nation’s 21 million health care workers and three million residents of long-term care facilities were the first to qualify. In mid-January, federal officials urged all states to open up eligibility to everyone 65 and older and to adults of any age with medical conditions that put them at high risk of becoming seriously ill or dying from Covid-19. Adults in the general population are at the back of the line. If federal and state health officials can clear up bottlenecks in vaccine distribution, everyone 16 and older will become eligible as early as this spring or early summer. The vaccine hasn’t been approved in children, although studies are underway. It may be months before a vaccine is available for anyone under the age of 16. Go to your state health website for up-to-date information on vaccination policies in your area

Is the vaccine free?

You should not have to pay anything out of pocket to get the vaccine, although you will be asked for insurance information. If you don’t have insurance, you should still be given the vaccine at no charge. Congress passed legislation this spring that bars insurers from applying any cost sharing, such as a co-payment or deductible. It layered on additional protections barring pharmacies, doctors and hospitals from billing patients, including those who are uninsured. Even so, health experts do worry that patients might stumble into loopholes that leave them vulnerable to surprise bills. This could happen to those who are charged a doctor visit fee along with their vaccine, or Americans who have certain types of health coverage that do not fall under the new rules. If you get your vaccine from a doctor’s office or urgent care clinic, talk to them about potential hidden charges. To be sure you won’t get a surprise bill, the best bet is to get your vaccine at a health department vaccination site or a local pharmacy once the shots become more widely available.

Can I choose which vaccine I get?How long will the vaccine last? Will I need another one next year?

That is to be determined. It’s possible that Covid-19 vaccinations will become an annual event, just like the flu shot. Or it may be that the benefits of the vaccine last longer than a year. We have to wait to see how durable the protection from the vaccines is. To determine this, researchers are going to be tracking vaccinated people to look for “breakthrough cases” — those people who get sick with Covid-19 despite vaccination. That is a sign of weakening protection and will give researchers clues about how long the vaccine lasts. They will also be monitoring levels of antibodies and T cells in the blood of vaccinated people to determine whether and when a booster shot might be needed. It’s conceivable that people may need boosters every few months, once a year or only every few years. It’s just a matter of waiting for the data.

Will my employer require vaccinations?Where can I find out more?

Dr. Stoffels said the company was still waiting for more data on whether the vaccine can protect against asymptomatic infection.

The company is preparing a lengthy briefing document it will submit to the F.D.A. in its application for authorization. The agency’s scientists will review the raw data from the trial and present their own analysis.

Unlike the messenger RNA vaccines made by Pfizer-BioNTech and Moderna, Johnson & Johnson uses an adenovirus, which normally causes the common cold. While adenovirus-based vaccines have been investigated for some three decades, they have yet to be licensed for use in the United States.

Johnson & Johnson’s Ebola vaccine became the first approved adenovirus-based vaccine for any disease when European regulators gave it the green light last July. Astra-Zeneca and the University of Oxford used a different adenovirus for their coronavirus vaccine, which is now authorized in Britain and other countries. Russian scientists created their Sputnik V vaccine from adenoviruses as well.

Johnson & Johnson received $456 million from Operation Warp Speed to support its research. In July, the government agreed to purchase 100 million doses for $1 billion if it proved safe and effective.

That same month, the company moved into clinical trials, which found that a single shot produced a strong immune response, consistent with experiments done on monkeys. Johnson & Johnson began the final “Phase 3” trial in September, again using a single dose. It recruited volunteers in the United States, South Africa and Latin America.

Half of the volunteers received the vaccine, and half received a placebo. The company then had to wait. Only when enough people in the trial got Covid-19 would an independent board of advisers look at the results to see how many sick volunteers were vaccinated — a process known as unblinding.

Late last year, surges of coronavirus infections accelerated the trial toward unblinding. In December, Johnson & Johnson decided it would not need to recruit 60,000 volunteers as it originally planned. It capped the trial at 45,000.

Like other vaccine developers, Johnson & Johnson was required by the F.D.A. to also record information about adverse events experienced by the volunteers for the first few months after vaccination.

Dr. Barouch, who led the team that designed the vaccine and tested it on animals last year, had to wait for months for the unblinding. “I’m thinking a lot about it,” he said in a Jan. 11 interview. “But, no, I don’t have champagne ready to go.”

After he learned the results, Dr. Barouch said he was delighted. “I think this vaccine will have a public health benefit throughout the world,” he said.

Johnson & Johnson is also moving forward with other trials of the vaccine to see how it can be improved. In December it began a trial with two doses. Dr. Fauci was optimistic that people who get a so-called prime boost may enjoy even more protection.

“If they get a prime boost, it’s entirely conceivable that they can get up to 90-plus percent,” he said.

In addition, Dr. Stoffels said that Johnson & Johnson was tailoring a version of its vaccine with a protein patterned after the B.1.351 variant. It could potentially deploy it in countries where that version of the virus was a threat.

“Pretty much all vaccine developers now are having that conversation,” said Dr. Peter J. Hotez, a vaccine expert with the Baylor School of Medicine and the creator of a different coronavirus vaccine.

Categories
World News

Dow futures prolong losses after J&J says vaccine much less efficient in opposition to some Covid variants

U.S. stock futures were significantly lower in early Friday trading after Johnson & Johnson said its one-off coronavirus vaccine showed less effectiveness in some regions.

The average Dow Jones Industrial futures lost 160 points, or 0.5%. S&P 500 futures lost 0.3%. Nasdaq 100 futures were down 1.5%.

Futures accelerated losses after JNJ said its single-dose vaccine had shown an overall 66% effectiveness in protecting against Covid-19. The vaccine was 72% effective in the US, 66% in Latin America, and 57% in South Africa at four weeks. The vaccine provided full protection against hospital stays related to Covid. JNJ’s shares fell 3.7% in the pre-market.

Stocks had rebounded to hit record highs in hopes that vaccines against Covid would be effective to allow for a smooth economic reopening before the end of the year. New mutations that are more resistant to vaccines could improve the bright outlook for investors.

Increased speculative trading by private investors also continued to worry the market. GameStop’s shares doubled in premarket trading after Robinhood announced it would restrict purchases of the stock and other heavily shortened names after restricting access the previous day. Robinhood raised more than $ 1 billion overnight from its existing investors and also used the banks’ credit lines to ensure that the capital was in place to start trading the volatile stocks again.

Investors are concerned that if GameStop continues to rise in such volatility, it could penetrate financial markets and cause losses at brokers like Robinhood and force hedge funds that bet against the stock to sell other stocks to raise cash.

There are also fears that the GameStop mania is a sign of a bigger bubble in the market, and that its dissolution could also create turmoil and hit retail investors hard. Several e-brokers took steps Thursday to curb intentional buying of highly speculative names. A number of lawmakers also called for an investigation into the chaotic trade.

“Between calling for hearings and reports in Washington, Robinhood was forced to not only draw on its credit lines but also raise $ 1 billion from existing investors. The whole situation continues to undermine market confidence,” said Adam Crisafulli, founder of Vital Knowledge, note in a Friday.

It’s been a volatile week on Wall Street. The Dow lost more than 600 points on Wednesday and suffered its worst sell-off in three months. Then the blue chip benchmark rallied 300 points on Thursday amid a broad market rally. All three major averages have lost at least 1% this week.

The market also saw its highest trading volume in years as the mania heated up. On Wednesday, the total market volume reached more than 23.7 billion shares, surpassing the level at the height of the financial crisis in 2008. On Thursday, there was also extremely strong trading with more than 19 billion shares that changed hands.

A wave of retailers motivated each other on the red-hot WallStreetBets Reddit forum to pile into the most hated names of hedge funds, resulting in massive short-bruising of stocks. GameStop is up more than 900% in January, while AMC Entertainment is up over 300% this month.

“This smaller capitalization rally would likely destabilize and lead to inefficiencies,” Christopher Harvey, senior equity analyst at Wells Fargo, said in a note. “Stocks are ultimately fundamentals – and reversals can be very painful, both up and down.”

However, some believe that the impact on the overall market should be limited as the retail crowd is focused on only a handful of names.

“While we believe there will be more pain, we remain optimistic that it will likely stay local,” said Maneesh Deshpande, head of equity derivatives strategy at Barclays. “Long-short hedge funds have relatively little market exposure, which indicates little impact on the overall market due to deleveraging.”

Subscribe to CNBC PRO for exclusive insights and analysis as well as live business day programs from around the world.

Categories
Health

Thailand finance minister on vaccine rollout, tourism restoration

SINGAPORE – Thailand will receive its first batch of vaccines next month and plans to produce its own vaccines, according to finance ministers.

Initially, about 100,000 cans will arrive, Arkhom Termpittayapaisith told CNBC’s “Squawk Box Asia” on Friday.

“The first vaccines will be coming to Thailand next month, the first lot,” he said, adding that Thai company Siam Bioscience will be working with Anglo-Swedish pharmaceutical company AstraZeneca to develop vaccines that will be useful for both Thailand and other countries are available.

He spoke to CNBC as part of the coverage of the World Economic Forum’s Davos agenda.

Thailand will begin rolling out vaccines on Feb. 14 and intends to vaccinate 19 million people in the first phase, its prime minister said on Wednesday, according to a Reuters report.

The Southeast Asian nation has According to the report, 26 million cans of AstraZeneca to be made by Siam Bioscience and 2 million cans of China’s Sinovac were secured. It has also reserved 35 million cans from AstraZeneca, it added.

Pandemic meets tourism

Termpittayapaisith also said tourism is expected to recover by the end of the year rather than mid-year as forecast. The Thai economy relies heavily on tourism for its growth, but the arrivals of foreign tourists almost completely stalled during the pandemic.

Tourist arrivals fell 66% to 6.69 million in the first six months of 2020 as countries around the world imposed bans and travel restrictions due to the pandemic.

By comparison, Thailand had a record 39.8 million tourists in 2019, according to Reuters. Tourist spending represented around 11% of Thailand’s GDP that year, the report said.

Commuters wearing face masks wait for a canal boat in Bangkok on March 2, 2020.

MLADEN ANTONOV | AFP | Getty Images

“We’re also focusing on domestic consumption so you can see that the economic package … encourages more spending on the basic economy,” Termpittayapaisith said, adding that it aims to offset the decline in international tourism revenue.

Thailand lowered its forecast for economic growth for this year from 4.5% to 2.8% on Thursday. According to the central bank, the economy is expected to shrink by 6.6% in 2020.

The country reported a record 959 cases on Tuesday, the highest daily increase since early January when it accelerated its testing, according to Reuters.

Thailand has one of the lowest reported cases in Southeast Asia. So far, 17,023 cases and 76 deaths have been reported, according to the Johns Hopkins University.

Categories
World News

Novavax’s Vaccine Works Effectively Besides on Variant First Present in South Africa

Here’s what you need to know:

Credit…Kenny Holston for The New York Times

Novavax, a little-known company supported by the U.S. federal government’s Operation Warp Speed, said for the first time on Thursday that its Covid-19 vaccine offered robust protection against the virus. But it also found that the vaccine is not as effective against the fast-spreading variant first discovered in South Africa, another setback in the global race to end a pandemic that has already killed more than 2.1 million people.

The news was problematic for the United States, which hours earlier reported its first known cases of the contagious variant in two unrelated people in South Carolina. And it came just days after Moderna and Pfizer said that their vaccines were also less effective against the same variant.

Novavax, which makes one of six vaccine candidates supported by Operation Warp Speed last summer, has been running trials in Britain, South Africa, the United States and Mexico. It said Thursday that an early analysis of its 15,000-person trial in Britain revealed that the two-dose vaccine had an efficacy rate of nearly 90 percent there. But in a small trial in South Africa, the efficacy rate dropped to just under 50 percent. Almost all the cases that scientists have analyzed there so far were caused by the variant, known as B.1.351. The data also showed that many trial participants were infected with the variant even after they had already had Covid-19.

“We have the first trial — we are the first to conduct an efficacy trial — in the face of a changing virus,” said Stanley Erck, the president and chief executive of Novavax. He said that researchers expected the variants could change the trial results, but “the amount of change has been a bit of a surprise to everyone.”

The South Africa trial was relatively small — with just 4,400 volunteers — and was not designed to come up with a precise estimate of how much protection the vaccine provides. Still, the results were striking enough that the company said it would soon begin testing a new vaccine tailored to protect against the variant from South Africa. “You’re going to have to make new vaccines,” Mr. Erck said.

While the Pfizer and Moderna vaccines rely on a newer mRNA technology that has not been used in previous vaccines, Novavax’s candidate employs an older, more established method that relies on injecting coronavirus proteins to provoke an immune response.

The fact that three vaccines all appeared to show lowered effectiveness against the variant from South Africa is not encouraging, and the results Novavax announced Thursday were the first to occur outside of a laboratory, testing how well a vaccine worked in people infected with a new variant. Johnson & Johnson is also on the cusp of announcing results of its Covid-19 vaccine trials, and has also tested its candidate in South Africa.

The announcement from Novavax raises the stakes for Johnson & Johnson. The company was expected to announce its results as early as last weekend, and the delay has triggered speculation among scientists that the firm has also discovered that its vaccine worked less well in South African trial volunteers who were infected with the variant. In an earnings call on Tuesday, Alex Gorsky, the chief executive officer of the company, said they were looking forward to sharing results from their late-stage trial by early next week.

The emergence of several highly contagious variants has complicated efforts to bring the pandemic under control, leading world leaders to shut down travel to places like Britain and South Africa even as the variants already appear to have circled the globe. In the United States, researchers have warned that the variant first identified in Britain, which is believed to be more infectious, could become the dominant form of the virus in this country by March.

The United States is well behind other countries in testing for such variants, and the one from South Africa has been found in about 30 countries.

But experts have also said there are reasons for optimism, noting that the vaccines remain effective. The best way to combat contagious new variants is to continue vaccination and other public health measures, which will slow the virus’s ability to infect new people and mutate further. Drug makers could update their vaccines and offer new shots at regular intervals, similar to the flu vaccine.

United States › United StatesOn Jan. 28 14-day change
New cases 165,073 –34%
New deaths 3,862 –2%
World › WorldOn Jan. 28 14-day change
New cases 603,201 –22%
New deaths 16,811 +4%

U.S. vaccinations ›

Where states are reporting vaccines given

Vaccines being given out in the Bronx this week. Credit…James Estrin/The New York Times

In his final State of the City address, Mayor Bill de Blasio offered a sprawling vision of New York City’s recovery from a pandemic that has taken tens of thousands of lives and destroyed the city’s economy.

The mayor committed to accelerating the city’s vaccination efforts and set a goal of inoculating five million New Yorkers by June.

He also said he would begin in May to bring back to offices the thousands of city employees who have been working remotely, and would safely reopen schools for all students in September.

“New York City’s vaccination effort is the foundation of a recovery for all of us,” the mayor’s 18-page recovery plan says. “With every vaccine shot, New York City moves closer and closer to fully reopening our economy, restoring the jobs we lost and ensuring equality in our comeback.”

If the federal government provides enough stimulus dollars to the city, Mr. de Blasio said, he will create a City Cleanup Corps of 10,000 temporary workers to focus on beautifying the city — an idea he compared to President Franklin D. Roosevelt’s Works Progress Administration during the Great Depression.

Mr. de Blasio also proposed two plans to help small businesses: a $50 million “recovery tax credit” program for businesses that have faced hardships from the pandemic, and a $100 million “recovery loan” program to help shops stay open. The city will provide low-interest loans of up to $100,000 to roughly 2,000 small businesses, according to the mayor’s plan.

But Mr. de Blasio has also warned that the city is facing major budget cuts and layoffs. He recently announced that the city’s property tax revenues are projected to decline by $2.5 billion next year, driven by a drop in the value of office buildings and hotel properties that have emptied out during the pandemic.

Mr. de Blasio and Gov. Andrew M. Cuomo have expressed optimism that President Biden, along with a Democratic-led Congress, will bring substantial assistance to the city. Mr. de Blasio also called for higher taxes on wealthy New Yorkers in his speech — a policy he has pushed for years, but that Mr. Cuomo has opposed.

Mr. de Blasio noted that more than 100 billionaires in the state increased their net worth by billions of dollars during the pandemic and called again for a redistribution of wealth.

“There is clearly enough money in New York to invest in a fair and fast recovery — it’s just in the wrong hands,” he said.

A former Kmart store is being used for a coronavirus vaccination site in Greenville, S.C. State officials have found a new variant of the virus in two patients in the state.Credit…Travis Dove for The New York Times

Health officials in South Carolina said on Thursday that they had detected two cases of a more contagious variant of the coronavirus that emerged in South Africa. It was the first report of that variant being detected in the United States.

The South Carolina Department of Health and Environmental Control said it had identified one case on Wednesday, and was notified of a second case the same day by the Centers for Disease Control and Prevention. The variant, known as B.1.351, was originally identified in South Africa and has since been found in about 30 countries.

The United States is conducting little of the genomic sequencing necessary to track the spread of new variants that have caused concern. They include B.1.1.7, first found in Britain and since seen in more than 46 countries and 24 U.S. states, and the P.1 variant, first found in Brazil, which officials in the United States reported detecting this week in Minnesota.

While the two coronavirus vaccines now in use in the United States, developed by Moderna and Pfizer-BioNTech, appear to be protective against the new variants, they may be somewhat less effective against the one found in South Africa. Moderna has begun developing a new form of its vaccine that could be used as a booster shot against the variant in South Africa. The new variants are also believed to spread more readily than other versions of the virus, and the one found in Britain may lead to more severe disease.

A little-known company, Novavax, which has been supported by the U.S. federal government’s Operation Warp Speed program, said for the first time on Thursday that its Covid-19 vaccine, offered robust protection against the virus. But it also found that the vaccine is not as effective against the fast-spreading variant first discovered in South Africa, another setback in the global race to end a pandemic that has already killed more than 2.1 million people.

As of Thursday afternoon, the Centers for Disease Control and Prevention said about 21.7 million people have received at least one dose of a Covid-19 vaccine, and that about 4.3 million people have been fully vaccinated.

The statement from South Carolina’s health department said that the cases involved no known travel to South Africa and no connection between the two patients, both adults, suggesting that the variant is circulating in the community. One patient was in the southern Lowcountry region of the state, and the other in the Pee Dee region in the northeast.

“The arrival of the SARS-CoV-2 variant in our state is an important reminder to all South Carolinians that the fight against this deadly virus is far from over,” Dr. Brannon Traxler, the department’s interim public health director, said in a statement. “While more Covid-19 vaccines are on the way, supplies are still limited. Every one of us must recommit to the fight by recognizing that we are all on the front lines now.”

At an online briefing, Dr. Traxler said that the same precautions were being taken for the new variant as for other virus cases. Both of the people who contracted the variant were tested in early January and have recovered, she said.

Gov. Henry McMaster wrote on Twitter that the announcement was “important information for South Carolinians to have, but it isn’t a reason for panic” and encouraged residents to wear masks and socially distance.

The C.D.C. said in a statement on Thursday that it was aware of South Carolina’s finding and that it would work to increase genomic sequencing across the country to track virus variants. The agency reiterated its warning against travel at this time.

Starting in March, Britain created an intensive program to track the genetic evolution of the coronavirus, and has sequenced more than 200,000 coronavirus genomes so far — nearly two-thirds of all the ones sequenced in the world. That success is probably why it became the first country to identify the B.1.1.7 virus, in December.

President Biden’s coronavirus czar, Jeffrey D. Zients, said on Wednesday that the United States was woefully behind other nations in tracking the variants, and he used the first White House public health briefing to issue a stark warning that Americans will remain vulnerable to the deadly pandemic unless Congress acts.

On Monday, Mr. Biden issued a ban on noncitizens entering the United States if they have been in South Africa within 14 days, because of concern over the variant. It will go into effect on Saturday. American citizens and permanent residents are not affected, officials said. Asked about the timing of the order at a briefing on Thursday, Jen Psaki, the White House press secretary, said that it took some time to work with airlines and regulatory authorities to put restrictions in place.

“We did that as quickly as possible,” she said.

The administration has also extended bans on travel from Brazil and much of Europe, and imposed a new rule requiring proof of a recent negative virus test before travelers can enter the country.

The B.1.351 variant is predominant in South Africa now, and is driving up new case reports to record levels there and across sub-Saharan Africa, the World Health Organization said on Thursday.

“The variant, which was first detected in South Africa, has spread quickly beyond Africa, and so what’s keeping me awake at night right now is that it’s very likely circulating in a number of African countries,” Dr. Matshidiso Moeti, the W.H.O.’s regional director for Africa, said at a briefing.

Marc Santora contributed reporting.

The world’s leading health organizations are giving conflicting advice regarding vaccinations for pregnant women.Credit…Callaghan O’Hare/Reuters

Pregnant women looking for guidance on Covid-19 vaccines are facing confusion of the sort that has dogged the pandemic from the start: The world’s leading public health organizations — the U.S. Centers for Disease Control and Prevention and the World Health Organization — are offering contradictory advice.

The C.D.C.’s advisory committee urged pregnant women to consult with their doctors before rolling up their sleeves — a decision applauded by several women’s health organizations because it kept decision-making in the hands of the expecting mothers.

But the W.H.O. is recommending that pregnant women not receive the vaccines, unless they are at high risk from Covid-19 because of work exposures or chronic conditions. It issued guidance on the Moderna vaccine on Tuesday, stirring uncertainty among women and doctors on social media. (Earlier this month, it had published similar guidance on the Pfizer-BioNTech vaccine.)

Several experts expressed dismay at the W.H.O.’s stance, saying the risks to pregnant women from Covid were far greater than any theoretical harm from the vaccines.

“There are no documented risks to the fetus, there’s no theoretical risks, there’s no risk in animal studies,” from the vaccines, said Dr. Anne Lyerly, a bioethicist at the University of North Carolina, Chapel Hill.

The difference of opinion between the C.D.C. and the W.H.O. is not rooted in scientific evidence, but the lack of it: Pregnant women have been barred from participating in clinical trials of the vaccines, reflecting a long tradition of excluding pregnant women from biomedical research and one that is now being challenged.

While the rationale is ostensibly to protect women and their unborn children, prohibiting pregnant women from studies pushes the risk out of the carefully controlled environment of a clinical trial and into the real world.

Vaccines are generally considered to be safe, and pregnant women have been urged to be immunized for influenza and other diseases since the 1960s, even in the absence of rigorous clinical trials to test them.

“As obstetricians we are often faced with difficult decisions about using interventions in pregnancy that have not been properly tested in pregnancy,” said Dr. Denise Jamieson, an obstetrician at Emory University in Atlanta and a member of the Covid expert group at the American College of Obstetrics and Gynecology. The college strongly advocated including pregnant and breastfeeding women in the vaccine trials.

In a statement, the C.D.C. said on Thursday that based on how the Pfizer-BioNTech and Moderna vaccines work, “they are unlikely to pose a specific risk for pregnant women.”

The C.D.C.’s recommendation may make sense for the United States, where women may easily be able to consult with their health care providers, said Joachim Hombach, a health adviser to the W.H.O. on immunizations. But the W.H.O. provides guidance to many low and middle income countries where women do not have access to doctors or nurses, he said.

The W.H.O.’s recommendation was also made “in the context of limited supply” of the vaccines, Dr. Hombach said. “I don’t think the language is discouraging, but the language is stating the facts.”

Pfizer plans to begin a clinical study in pregnant women in the first half of 2021. Moderna said it was establishing a registry to record outcomes in pregnant women who receive its vaccine.

Emergency medical technicians lifting a man after moving him from a nursing home into an ambulance in Brooklyn.Credit…Lucas Jackson/Reuters

An investigation by the New York State attorney general has concluded that Gov. Andrew M. Cuomo’s administration undercounted coronavirus-related deaths at nursing homes by as much as 50 percent.

The count of deaths in state nursing homes has been a source of controversy for Mr. Cuomo and state Health Department officials, who have been sensitive to any suggestion that decisions made at the outset of the pandemic may have caused some of those deaths, which the state puts at more than 8,700.

They have also been accused of obscuring a more accurate estimate of nursing home deaths, because the state only counted deaths at the actual facilities, rather than including deaths of residents who were transferred to a hospital and died there.

In the 76-page report released on Thursday by the attorney general, Letitia James, a survey of nursing homes found consistent discrepancies between deaths reported to the attorney general’s investigators and those reported to and officially released by the Health Department.

In one instance, an unnamed facility reported to the Health Department that it had 11 confirmed and presumed deaths on site through early August. The attorney general’s survey of that same facility, however, found 40 deaths, including 27 at the home and 13 in hospitals.

Another facility reported one confirmed and six presumed Covid-19 deaths to the Health Department, according to the report. The attorney general’s office, however, said the facility reported to its investigators that there were more than four times that number — 31 dead — by mid-April.

Deaths in nursing homes and other long-term care facilities have accounted for about a third of the nation’s some 430,000 deaths. Federal and state authorities have made vaccinating staff and residents at such facilities a top priority, though that effort has been slower than hoped.

In New York, where there have been more than 42,000 virus-related deaths, the toll in the state’s nursing homes has been a particular source of agony for residents and their families. It has also been a political liability for Mr. Cuomo, who has pushed back on accusations that his administration did not do enough to safeguard a highly vulnerable population.

The findings of Ms. James would seem to put her in rare conflict with Mr. Cuomo, the state’s three-term Democratic incumbent. Ms. James was the governor’s favored choice to succeed Eric T. Schneiderman after he suddenly resigned as attorney general in 2018; she readily embraced Mr. Cuomo’s political backing.

The attorney general asked 62 nursing homes — about a tenth of the state’s total — for information about on-site and in-hospital deaths related to the virus; investigators then cross-referenced that information with public reports of deaths issued by the Health Department. The deaths reported to the attorney general’s office at most of those facilities totaled 1,914, compared to the state’s much lower count of 1,229.

Ms. James said that her office was investigating those circumstances “where the discrepancies cannot reasonably be accounted for by error or the difference in the question posed.”

The attorney general said she was continuing to conduct investigations of more than 20 nursing homes across the state that “presented particular concern,” noting that “other law enforcement agencies also have ongoing investigations relating to nursing homes.”

The Overlake Medical Center in Bellevue, Wash., last spring.Credit…Grant Hindsley for The New York Times

A Washington hospital system apologized after The Seattle Times reported that it had offered vaccines to wealthy donors while others went without the coveted shots.

Overlake Medical Center & Clinics sent an email to about 110 donors who gave more than $10,000 to the hospital system, telling them they could register for open appointments “by invite” only.

The report drew a rebuke from Gov. Jay Inslee, who said during a news conference on Tuesday that the practice was “simply unacceptable.”

Overlake’s president and chief executive, J. Michael Marsh, apologized in a statement, adding that even those donors would have been required to show that they were eligible for the vaccine under state guidelines.

“We recognize we made a mistake by including a subset of our donors and by not adopting a broader outreach strategy to fill these appointments, and we apologize,” Mr. Marsh said.

The hospital’s conduct mirrors that of other facilities that have made news for prioritizing wealthy donors over the rest of the population. A Florida nursing home and assisted living facility called MorseLife Health System came under investigation after The Washington Post and The New York Post reported that it had prioritized its donors as well.

Another, Baptist Health in Miami, invited a donor to get a shot. The recipient said she believed she was offered a vaccine because she had donated and volunteered for the hospital.

And in Jefferson City, widespread confusion led some Missouri lawmakers to scramble for shots that were not intended for them. Group texts among House members and staff said vaccines were available at an area hotel, but the shots were meant for the state’s public safety and transportation employees.

Mr. Inslee said during Tuesday’s news conference that Washington State’s biggest barrier to widespread vaccine distribution was supply. As of Thursday, 6.2 percent of the state’s population had received their first dose. Just 1.2 percent had received the full two doses.

After hearing of the prioritizing of donors, Mr. Inslee said he believed that the hospital had halted that practice.

“We have to maintain public credibility in this system,” he said.

The vaccination site at the Pennsylvania Convention Center in Philadelphia earlier this month.Credit…Kimberly Paynter/WHYY

With pressure mounting to get Covid-19 vaccine doses into arms as quickly as possible, many overburdened city health departments across the country have turned to partnerships with hospitals, nonprofit organizations and pharmacies. In Philadelphia this week, one such deal went awry after the city leaned on a start-up led by college students who were eager to get involved but had little experience.

The start-up is an organization called Philly Fighting Covid, which was founded last year by a 22-year-old graduate student, Andrei Doroshin. The group quickly won plaudits for volunteering to run free testing sites, and for using 3-D printers to make face shields that it supplied free to health care workers.

So when Philadelphia began receiving shipments of vaccine and needed help administering doses on a large scale, the city health department turned to Philly Fighting Covid to operate what would be the largest vaccination site in the state, at the Pennsylvania Convention Center.

It took less than three weeks after vaccinations began for the partnership to sour.

Since it opened on Jan. 8, the site has vaccinated nearly 7,000 people, though there were reports in local media that appointments had been overbooked and some people were turned away. Mr. Doroshin attributed those problems to issues with an online sign-up system that allowed thousands of ineligible people to register for appointments.

Then on Tuesday, the city health commissioner, Thomas Farley, said at a news conference that the health department would no longer work with Philly Fighting Covid. The city learned, he said, that the group had unexpectedly canceled its testing efforts to focus on vaccination; that it planned to change from nonprofit status to a for-profit company; and that it had changed its data privacy policy to allow it to potentially sell data about patients to third parties, a step first reported by the public radio station WHYY.

“We did not think that was appropriate,” Dr. Farley said about the data policy. “We thought, ‘If there’s any attempt to do this, even the possibility, then people won’t trust this organization.’”

In an interview, Mr. Doroshin said his group had only the best intentions, but he acknowledged its inexperience.

“We’re a bunch of kids,” Mr. Doroshin said. “I didn’t know anything about legal structure before this. I didn’t care. I’m not a lawyer, I’m a nerd. People are trying to make me out to be this nefarious thing. I’m like, ‘Dude, I didn’t know all the rules of a nonprofit organization until I did this.’”

He said that the company had decided to switch to a for-profit structure in order to expand quickly, and that it had not hid its intentions from the city.

Mr. Doroshin did acknowledge that there were problems with the organization’s privacy policy, which he said was posted in haste. But he said that the group had not sold or otherwise disseminated any of the patient data it collected, and that the posted policy “was frankly just a mistake.”

Katrina Lipinsky, a registered nurse who volunteered at the group’s vaccination site, said in an interview that at the end of one day, after the group tried to find takers for a number of leftover doses, she saw Mr. Doroshin put a few in his backpack, along with the vaccination cards that are used to track vaccination timelines. She said she had reported it to city investigators.

“Obviously, that didn’t seem right,” she said.

Dr. Farley, the health commissioner, told reporters that any leftover vaccine doses should have been given back to the health department. He said the department was looking into the matter.

“If that’s true, that’s very disturbing,” he said. “They shouldn’t have done that.”

In the interview, Mr. Doroshin acknowledged that he took four doses home with him and administered them to friends. He said that he should have had a nurse present when he gave the shots, but that he did not regret making use of doses that would otherwise have expired that night.

“I’m OK with being a person that broke a rule to not have any vaccine left over,” he said. “If that’s the final word I have in my book, then that’s OK. I’m OK with dying with that.”

About a third of U.S. school are entirely remote.Credit…Bridget Bennett for The New York Times

Dr. Anthony S. Fauci, addressing more than 6,000 American teachers in a video meeting, said Thursday evening that students need to return to the classroom for the country to begin recovering.

“We are not going to get back to normal until we get the children back in school, for the good of the children, the good of the parents and the good of the community,” he said.

Attending a meeting convened by the two national teachers unions, Dr. Fauci brought with him the message of the Biden administration: that all K-8 schools should aim to reopen within the next 100 days. He said they can expect support from Washington in the form of a new stimulus package to fund sanitation upgrades and other safety measures.

As of last month, about one third of American school districts were operating entirely remotely, and Dr. Fauci acknowledged that “mitigating factors” may make the 100-day goal difficult to achieve in some places.

Fielding questions submitted by educators, he did not hesitate to acknowledge potential dangers.

He discussed the emergence of new variants of the coronavirus that appear more contagious and more resistant to vaccines. And he said that while he expected vaccines to prevent inoculated teachers from passing the virus onto their loved ones, there was not yet concrete evidence that would be the case.

As Dr. Fauci spoke, educators at the meeting posted comments — many reflecting frustration and anxiety. They complained that many states had not prioritized teachers for vaccination and said students were not able to effectively stay masked throughout the school day.

Several called for job actions.

“Teachers need to participate in a national strike to protect kids, communities, and teachers,” one wrote.

Dr. Fauci appeared alongside two powerful teachers union presidents: Randi Weingarten of the American Federation of Teachers and Becky Pringle of the National Education Association.

The event took place as some local unions across the country, most notably in Chicago, continue to resist efforts to reopen schools, arguing that doing so before widespread teacher vaccination would risk lives.

Ms. Weingarten has staked out a somewhat more moderate position, arguing that schools can operate safely before teachers are vaccinated by using strategies such as surveillance testing for the virus and updating ventilation systems. She has also asked for teachers with health concerns, or who live with family members with compromised immune systems, to be allowed to continue to work remotely.

Global roundup

A vaccination center in Berlin last month.Credit…Lena Mucha for The New York Times

Chancellor Angela Merkel will convene the governors of Germany’s 16 states, along with representatives of pharmaceutical companies to discuss the country’s troubled vaccination scheme, after her health minister, Jens Spahn, warned that the country is facing another 10 weeks of vaccine shortages.

The situation has increasingly angered Germans who were promised an efficient immunization campaign. Even the most vulnerable have struggled to get access to the potentially lifesaving shots.

The German government helped fund development of the Pfizer-BioNTech vaccine with 738 million euros, or about $895 million, only to see it first administered in Britain. But many immunization centers set up across Germany stand empty, and older adults who were to be among the first to be vaccinated have been turned away.

“We are facing at least 10 hard weeks, given the lack of vaccines,” Mr. Spahn said on Twitter on Thursday.

Instead of approving and purchasing vaccine doses on its own, Germany chose to band together with 26 other European Union countries to ensure equal access across the bloc. But the process has been slowed by squabbling between members over sluggish vaccine production. This week, it became further bogged down by a dispute with the British-Swedish pharmaceutical maker AstraZeneca, after the company announced that it would not be able to meet its delivery quotas to the European Union.

In other news from around the world:

  • Chinese officials said on Thursday that several passengers traveling to China from the United States had falsified coronavirus test results so they could gain entry to the country. The Chinese consulate in San Francisco said the passengers “changed their test results from positive to negative” and that other travelers had lied about their results. The consulate did not provide details about the passengers or the punishments they might face. China maintains strict border control rules, including a requirement that travelers present results from antibody and nucleic acid tests before they fly. The consulate said the passengers violated public health laws. “The way they put others at risk is odious,” the statement said.

  • In the Philippines, the Food and Drug Administration granted emergency approval on Thursday to the AstraZeneca vaccine, saying that it was 70 percent effective after the first of two doses. The country has reported more than 500,000 cases and 10,000 deaths during the pandemic, second only to Indonesia in Southeast Asia. It has signed a deal with AstraZeneca for 17 million doses, with the first expected to arrive in May.

  • Japan’s national broadcaster reported on Thursday that the International Swimming Federation, known as FINA, planned to postpone its artistic-swimming qualification event for the Tokyo Olympics because of the coronavirus. The competition, which was to be held at the Tokyo Aquatics Center in March, would have been the first test event for the reorganized Summer Games. It was rescheduled for May.

  • A businessman from Taiwan has been fined more than $35,000 after he was caught on camera repeatedly breaking rules requiring him to quarantine at home. The man, who returned to Taiwan last week from mainland China, left his home seven times when he was supposed to be in isolation, according to officials in the city of Taichung, where he lives. Taiwan has some of the strictest quarantine rules in the world, a critical part of its success in fighting the virus, and the government routinely punishes and shames people found to be violating regulations. “This misbehavior was serious and must be punished heavily,” Lu Shiow-yen, the mayor of Taichung, said at a news conference this week.

After 117 years in business, Harrell’s Department Store in Burgaw, N.C., became a casualty of the pandemic.Credit…Jeremy M. Lange for The New York Times

The economic upheaval caused by the pandemic is changing communities across the country as hundreds of thousands of businesses close, leading to lost livelihoods and empty storefronts.

Many of these businesses were neighborhood pillars, beloved locales that we returned to over and over again.

In your neighborhood, maybe it was the bar where you met friends after work, the restaurant where your family celebrated birthdays or the bookstore where you loved to browse.

Now they are gone.

The New York Times would like to hear from you about a local business that has shut down. Why was it special to you, and what do you miss about it? How is its absence altering the fabric of your community?

Tell us about it here.

We may contact you with a few follow-up questions. And if you can, please share a photo of the business as well.

Video

transcript

Back

transcript

E.U. Pushes for AstraZeneca to Provide More Vaccines

The European Union is pushing for AstraZeneca to supply more doses of its Covid-19 vaccine after announcing on Wednesday that it would cut deliveries by 60 percent due to manufacturing issues.

Not being able to ensure manufacturing capacity is against the letter and the spirit of our agreement. We reject the logic of first come, first served. That may work at the neighborhood butcher’s, but not in contracts, and not in our advanced purchase agreements. There’s no priority clause in the advance purchase agreement, and also there’s also no hierarchy of the full production plants named in the advance purchase agreement. In the contracts, there are four, I think, four factories listed, but it does not differentiate between the U.K. and the Europe — the U.K. factories are part of our advance purchase agreements, and this is why they have to deliver. Pharmaceutical companies, vaccine developers have moral, societal and contractual responsibilities, which they need to uphold. The view that the company is not obliged to deliver because we signed a best effort agreement is neither correct nor is it acceptable.

Video player loadingThe European Union is pushing for AstraZeneca to supply more doses of its Covid-19 vaccine after announcing on Wednesday that it would cut deliveries by 60 percent due to manufacturing issues.CreditCredit…Manu Brabo/Getty Images

“Tomorrow our fridges will be empty.”

That warning came from Josep Maria Argimon, a health official in Catalonia, and he was referring not to food but to the dwindling supplies of something almost as precious: the coronavirus vaccine.

On Wednesday, Spain became the first European country to partly suspend immunizations because of a lack of doses. It did so first in Madrid, for two weeks, and said that Catalonia, the northeastern region that includes Barcelona, could soon follow.

It has not gone easily for the European Union since it approved its first vaccine in late December and rushed to begin a vast immunization campaign across its 27 member states.

But the early problems have snowballed into a full-blown crisis.

Countries across the bloc have felt the pain of vaccine shortages even as a new wave of the virus rages. The pandemic has prompted prolonged lockdowns in most member countries, and there is also anxiety over the spread of at least two highly infectious variants that are straining national health systems.

It is unclear when the supply might improve.

The bloc is also in an escalating dispute with AstraZeneca over the drug maker’s announcement that it would cut deliveries by 60 percent because of production shortfalls. And Pfizer informed the European Union this month that it had to drastically cut its vaccine deliveries until mid-February while it upgraded its plants to ramp up output, adding to the supply problems.

In a rare bit of good news, the French drug maker Sanofi said on Wednesday that it would help produce more than 100 million doses of the Pfizer-BioNTech vaccine, starting this summer — but those doses will most likely come too late to salvage vaccination plans for the first half of 2021.

When the European Union approved its first vaccine in December, it was already weeks behind nations like the United States and Britain. While it is flush with cash, influence and negotiating heft, the bloc of 27 nations has also found itself lagging countries such as Israel, Canada and the United Arab Emirates.

Last week, the European Union’s executive branch, the European Commission, set a goal of having 70 percent of its population inoculated by this summer. Just days later, the president of the European Council, Charles Michel, pronounced that “difficult.”

As of this week, a mere 2 percent of E.U. citizens had received at least one dose of a coronavirus vaccine, according to numbers collected by the research site Our World in Data. That compares with around 40 percent for Israel, 11 percent for Britain and just over 6 percent for the United States.

Many countries, particularly poorer ones, are struggling to secure any vaccines at all. But the delays in Europe have created tensions.

Some critics have blamed the European Commission, which struck deals on behalf of the member states to secure a total of 2.3 billion vaccine doses from several companies.

Some of its agreements were struck weeks after those reached by the United States and Britain. AstraZeneca and some European opposition politicians say that the delay put the bloc at the back of the line for deliveries. The commission has challenged those claims.

“We reject the logic of first-come, first-served,” the bloc’s heath commissioner, Stella Kyriakides, said at a news conference on Wednesday. “That may work at the neighborhood butcher, but not in contracts and not in our advanced purchase agreements.”

Preparing a dose of the AstraZeneca vaccine.Credit…Silvia Izquierdo/Associated Press

Germany’s vaccination advisory committee, which provides recommendations to the government, is cautioning against using the AstraZeneca shot on adults age 65 and above, saying in a draft report released on Thursday that “there currently is not sufficient data to assess the vaccination effectiveness above 65 years.”

The German Health Ministry, which usually follows the advice of the committee, declined to comment. The European Medicines Agency, the regulatory body for the European Union, is expected to announce on Friday whether the vaccine will be approved for use in the bloc. Britain has been administering the AstraZeneca shots to all age groups after it became the first country to give the vaccine emergency authorization, in December.

British regulators have said that data on the efficacy and safety of the vaccine “are currently limited” in people age 65 and older.

But concerns about the scarce data on older people could limit the use of the AstraZeneca shot: European regulators are considering authorizing it only for people under 65, two E.U. officials said.

Neither AstraZeneca nor Oxford University, which helped develop the vaccine, has released figures on how effective the shot is in older people. But data on older people’s immune responses have suggested that the vaccine will help protect them from the virus, the company has said.

The Oxford team, which was in charge of the earliest trials of the vaccine, did not want to vaccinate older people until they had collected extensive safety data for younger participants, Pascal Soriot, the chief executive of AstraZeneca, said in an interview with La Repubblica, an Italian newspaper, this week.

Other vaccine makers, Mr. Soriot said, decided to vaccinate older people in trials before they had accumulated as much safety data, allowing them to make stronger claims about efficacy in that age group.

In the United States, the Food and Drug Administration is waiting on data from a clinical trial that enrolled about 30,000 participants, mostly Americans, and that will include more older people. The results are expected in the coming weeks. AstraZeneca is expected to have sufficient safety data from that study to file for emergency use authorization from the F.D.A. around the first week of March.

Benjamin Mueller and Rebecca Robbins contributed reporting.

Video

transcript

Back

transcript

Health Care Orders Undo ‘Damage Trump Has Done,’ Biden Says

President Biden took executive action to expand health care access by strengthening the Affordable Care Act and reopening enrollment. He also moved to protect reproductive rights and expand abortion access.

Today, we’re about to sign two executive orders. Basically, the best way to describe it, to undo the damage Trump has done. There’s nothing new that we’re doing. The first one I’m going to be signing here is to strengthen Medicaid and the Affordable Care Act. And of all times that we need to reinstate access to affordability of and extent of access to Medicaid, is now, in the middle of this Covid crisis. And the second order I’m signing relates to protecting women’s health at home and abroad, and it reinstates the changes that were made in Title X and other things, making it harder for women to have access to affordable health care as it relates to reproductive rights.

Video player loadingPresident Biden took executive action to expand health care access by strengthening the Affordable Care Act and reopening enrollment. He also moved to protect reproductive rights and expand abortion access.CreditCredit…Doug Mills/The New York Times

President Biden, seeking to expand access to health care and strengthen the Affordable Care Act, used his executive authority Thursday to order the reopening of enrollment in the health law’s marketplaces and a re-examination of Trump administration policies that undermined protections for people with pre-existing medical conditions.

His aim, he said in a brief signing ceremony in the Oval Office, was to “undo the damage Trump has done.”

Mr. Biden also moved to protect reproductive rights and expand access to abortion, and took separate executive action to overturn his predecessor’s restrictions on the use of taxpayer dollars for clinics that refer or counsel patients to terminate pregnancies, both in the United States and overseas.

Taken together, Mr. Biden is trying to put a quick stamp on health policies that have been critical to a Democratic resurgence, especially those that back the Affordable Care Act, which he helped secure as President Barack Obama’s vice president. President Donald J. Trump failed to overturn the health law, but he spent four years undermining it with a series of executive actions, including allowing the sale of cheap, short-term and small-business health plans that do not meet the law’s health coverage mandates.

Mr. Biden’s first step is to reopen enrollment for health coverage offered through the federal marketplace created under the health law, also known as Obamacare. His intent is to offer coverage not only to those who lost it during the pandemic, but also to those who did not have insurance and now want it, according to a senior administration official who previewed the new policy during a conference call Thursday morning.

The so-called special enrollment period will run from Feb. 15 to May 15. The official said the reopening would be accompanied by the kind of robust patient outreach — including “paid advertising, direct outreach to consumers and partnerships” with community organizations and advocacy groups — that was abandoned by the Trump administration.

Typically, Americans in the 36 states that rely on the federal marketplace can buy Obamacare insurance only during a six-week period in the fall, a restriction meant to encourage people to hold coverage even when they are healthy. The sign-up period for this year’s coverage ended in mid-December, with enrollments only slightly higher than they were last year. But the Trump administration did little to advertise it.

Once the coronavirus struck, Mr. Trump faced pressure to reopen enrollment for the millions of Americans losing their jobs, but he refused.

Mr. Biden’s actions take aim at a number of Mr. Trump’s policies. In 2018, citing complaints about the price of Obamacare coverage, the Trump administration issued a rule that extended the length of less expensive “short” term policies from three months to up to three years. Such policies do not have to cover pre-existing conditions and can exclude common benefits like maternity care, mental health care or prescription drugs. The former administration also made it easier for small businesses to band together and offer plans that escape some of the requirements of the Affordable Care Act.

Mr. Biden has asked federal agencies to re-examine these rules, which could take months to undo. Should the rules be overturned, patients who have such policies would be unable to renew them, which could leave them without insurance if they think coverage is too expensive. Mr. Biden campaigned on raising the subsidies for Obamacare plans to make them more affordable.

Mr. Biden’s executive actions on abortion put him in the center of the nation’s long-running culture wars. Like his Democratic predecessors, Presidents Bill Clinton and Barack Obama, he will immediately rescind the global gag rule — often called the “Mexico City Policy” — which bars international nonprofit organizations that provide abortion counseling from using American tax dollars.

The rule has been riding a philosophical seesaw for decades — in place when a Republican occupies the White House, and overturned when a Democrat moves in.

Mr. Biden’s revocation of the Mexico City Policy was part of an order that restored funding terminated by Mr. Trump to the United Nations Population Fund, known as UNFPA, the world’s leading provider of family planning services, and a major resource for millions of women in more than 120 countries. Mr. Trump’s decision nearly four years ago was a shock to the UNFPA, which had counted on the United States, a founding member, as a critical source of funding. Overnight, the agency lost nearly $70 million.

Dr. Natalia Kanem, the fund’s executive director, welcomed Mr. Biden’s order, which she said would greatly help the agency’s work not only in family planning but in other health services to struggling women and girls in poor countries.

“We now have the support of a very important member state,” Dr. Kanem said in a phone interview, expressing gratitude that the Biden administration had embraced her agency’s work around the world.

Mr. Biden is also directing the Department of Health and Human Services to “take immediate action,” his administration said, to consider whether to rescind the so-called domestic gag rule — a regulation imposed by the Trump administration that prohibits family planning clinics that receive federal funding from counseling patients about abortion. Such a change would likely require the department to write new regulations, a process that could take months.

The president’s Obamacare directive will also instruct federal agencies to review policies — including waivers that allowed states to impose work requirements — that discourage participation in Medicaid, the public health insurance program for the poor and disabled. Enrollment in Medicaid has grown substantially during the coronavirus pandemic, in part because people who have lost jobs and their health insurance have turned to Medicaid for coverage.

President Biden swore in members of the White House staff remotely on Jan. 20.Credit…Doug Mills/The New York Times

Senior staff members in West Wing offices are prohibited from meeting together in an office for more than a total of 15 minutes in a day, according to a senior Biden administration official. No more than six people are allowed to gather in the Oval Office at a time, and a maximum of five staff members are allowed to meet together in the spacious office of the chief of staff, Ron Klain, the official said.

That means that both the morning and afternoon senior staff meetings in the White House are conducted on video calls, even though many of the participants are working in offices near one another.

In the Roosevelt Room, gatherings are limited to 10 people. And when staff members remove their masks to eat lunch at their desks, they are required to close their doors.

Visitors are not allowed without approval, and West Wing staff members generally do not intermingle with the team working in the Eisenhower Executive Office Building across the street.

As the new administration finds its footing, life in the West Wing has become incredibly disciplined, partly because of the way President Biden’s team wants to work, but mostly because of the strict rules the administration has put in place to prevent the spread of the coronavirus. Unlike an administration functioning during normal times, the Biden team can’t simply add people to a meeting at the last minute, or run someone into the building.

It couldn’t be more different in feel and temperament from the opening weeks of the Trump administration, when the Oval Office was often compared to Grand Central Terminal. Former President Donald J. Trump’s office served as a bustling focal point of all West Wing activity as aides wandered in and out and then simply hung about, once it was clear that there was no formal structure for meetings or policymaking, and that for Mr. Trump, out of sight was out of mind.

All West Wing staff members are still tested daily even though a growing number of administration officials are getting vaccinated. There are also fewer people working in the building, and those who are there rarely leave the campus for lunch. There have been awkward moments in hallways, when staff members don’t recognize each other because everyone is required to wear an N95 mask and many have opted to double-mask, officials said.

The measures are in place because of a realization that while it may be impossible to prevent the coronavirus from entering the White House complex entirely, it is possible to reduce the risk of widespread infection if someone on the president’s team gets sick. The rules have been put in place by Anne Filipic, the director of management and administration, and Jeff Wexler, the White House director of Covid-19 operations.

A White House spokesman would not confirm the number of people allowed in meetings, or the time limits on such gatherings. But he said that in-person meetings were limited and that colleagues were socially distancing.

So far, officials said, the measures appear to be working. But they concede that it’s a difficult way to run a White House, just as it was a difficult way to run a campaign and a difficult way to run a transition.

“Adjusting to doing most meetings via video and doing most of our work with colleagues remotely has not been a massive leap,” said Jen Psaki, the White House press secretary. “It has been a long adjustment as humans to not being able to hug old colleagues or shake hands with new ones, but so far we don’t feel that it has prevented us from doing our jobs.”

A street in Hanoi, Vietnam, on Thursday. The country reported 82 cases on Thursday, mostly in the northern province of Hai Duong.Credit…Luong Thai Linh/EPA, via Shutterstock

Vietnam reported 82 coronavirus infections on Thursday, the first cases of local transmission in nearly two months, and the government said that some may be connected to the new variant that has been spreading rapidly in Britain.

Prime Minister Nguyen Xuan Phuc has called on the two northern provinces where the cases were reported to close their borders to prevent people from leaving, the state-run news media reported on Thursday.

Vietnam has been relatively successful in containing the virus. Before the latest outbreak in the northern provinces, Hai Duong and Quang Ninh, the country had reported only about 1,550 cases and 35 deaths.

The new cases arrived at an inconvenient time. Officials from the governing Communist Party are meeting this week in Hanoi, the capital, to select their next leaders, an event that takes place once every five years. And people across the country are preparing to celebrate the Lunar New Year, Vietnam’s biggest holiday.

Vietnam’s largest outbreak occurred in July in the central city of Danang, sickening hundreds and causing all 35 of the country’s reported deaths before it was contained.

Health officials initially reported two new cases Thursday morning. But the number rose to 82 by the afternoon, after health workers began tracing and isolating the first patients’ contacts.

Of 138 people tested in Hai Duong, 72 were positive for the virus, Health Minister Nguyen Thanh Long said, according to a recording of comments made at an urgent meeting on the sidelines of the Communist Party congress. All of those patients work at a local electronics factory, local news media reported.

The first worker found to have contracted the virus is said to have had contact with a Vietnamese national who later traveled to Japan, where he tested positive for the variant that has spread in Britain.

The other 10 cases appear to have originated with a worker at Van Don International Airport in Quang Ninh Province who was responsible for taking arriving passengers to quarantine.

The Armory, an indoor track and field complex in Washington Heights, being set up as a coronavirus vaccination center on January 14.Credit…Mark Lennihan/Associated Press

A New York City health network changed its guidelines at a Covid-19 vaccination center in a predominantly Hispanic neighborhood after it was found to have been providing the scarce doses to suburbanites while local residents struggled to get appointments.

The health network, New York-Presbyterian, announced Wednesday that it would limit all new vaccine appointments at the center, in Washington Heights, to New York City residents effective immediately. Earlier this month, Gov. Andrew M. Cuomo touted the center as a way to combat inequity and to make sure “New Yorkers of color aren’t left behind.”

Black and Latino people are more likely to be affected by the virus than white people, and many minority communities have been suspicious of taking the vaccine in light of the history of unethical medical research in the United States. Officials have stressed the importance of making vaccines accessible to underserved communities.

However, a report this week by The City, a nonprofit news organization, found that no guides or guards at the center spoke Spanish, despite its location. Many patients entering the site “appeared to be white and unfamiliar with the neighborhood,” The City reported.

Until Wednesday, the center provided vaccinations to any patients who were eligible for the vaccine as long as they had an appointment. Now, a minimum of 60 percent of the appointment slots will be reserved for residents of Washington Heights and nearby neighborhoods in Manhattan and the South Bronx, according to the statement from New York-Presbyterian. (All existing appointments scheduled before Wednesday would still be honored.)

The health network added that “a dedicated outreach team that includes bilingual staff has been created to expand community outreach efforts in Northern Manhattan.”

At a news conference on Thursday, Mayor Bill de Blasio expressed frustration over the vaccine rollout at the center.

“What happened in Washington Heights is the exact opposite of what we need,” he said. “If a site is in a community, particularly a community hard hit by Covid, it should be all about reaching out to that community and bringing people in.”

Mr. de Blasio said that there had been 699,524 doses of vaccine administered in the city, but a shortage in the available supply was still slowing the vaccination effort.

He said the state had made available to the broader eligible population in the city some 18,000 doses that were slated for use in long-term care facilities, like nursing homes, but were not being used.

City and state officials have said that vaccinations would not be enough to end the pandemic. Mr. de Blasio said that the seven-day average rate of citywide positive test results was 8.09 percent, and had been trending downward over the past week. Still, 34 ZIP codes across the city had a seven-day average positive test rate at or over 10 percent, according to the most recently available data.

While Mr. Cuomo had said on Wednesday that the state was considering allowing indoor dining in the city to resume at 25 percent capacity, Mr. de Blasio on Thursday urged caution, particularly with the danger posed by new variants.

But he said he would be willing to eat indoors if the state allowed it.

“We all want to see indoor dining come back,” Mr. de Blasio said. “It has to be governed by the data and the science. The state will make that decision.”

Hankou Station in Wuhan, China, last week. A year ago, the station was among the first places to be closed after the coronavirus outbreak.Credit…Roman Pilipey/EPA, via Shutterstock

Every winter, Pang Qingguo, a fruit seller in northern China, makes the 800-mile trip to his ancestral home to celebrate the Lunar New Year, the biggest holiday of the year in China, with his family.

The coronavirus ruined the festivities last year, stranding Mr. Pang in the northern city of Tangshan as many Chinese cities imposed lockdowns. Now, as China confronts a resurgence of the virus, the pandemic is set to spoil the holiday again, with the authorities announcing onerous quarantine and testing rules to dissuade migrant workers like Mr. Pang from traveling for the new year, which begins this year on Feb. 12.

Mr. Pang, who describes his home in the northeastern province of Heilongjiang as the “happiest place,” is anguished by the rules. He has taken to social media in recent days to express frustration about his situation and post photographs of his 7-year-old daughter, whom he has not seen in more than a year. “Society is so cruel,” he wrote in one post.

Many of China’s roughly 300 million migrant workers face a similar reality as the government tries to avoid a surge in cases during what is typically the busiest travel season of the year.

The authorities have demanded that people visiting rural areas during the holiday spend two weeks in quarantine and pay for their own coronavirus tests. Many migrants, who endure grueling jobs for meager wages in big cities, say those restrictions make it impossible to travel.

The rollout of the rules has drawn widespread criticism in China, with many people calling the approach unfair to migrant workers, who have long been treated as second-class citizens under China’s strict household registration system. The workers have been among the most deeply affected by the pandemic, as the authorities have carried out scattered lockdowns to fight the virus and employers have reduced hours and pay.

In a regular year, hundreds of millions of people travel by plane, train and car to be with their families for the Lunar New Year. The holiday, which typically includes big festive banquets and fireworks, is normally the only time that many workers can return to their hometowns to see loved ones. This year, many are making plans to spend the holiday alone.

Troops and civilian residents at the U.S. naval base and military prison at Guantánamo Bay, Cuba, are already being vaccinated. Officials said shots would be offered to detainees as well.Credit…Alex Brandon/Associated Press

WASHINGTON — The Pentagon has decided to offer coronavirus vaccines to detainees at Guantánamo Bay, Cuba, possibly starting next week, according to a prosecutor in the case against five prisoners accused of conspiring in the attacks of Sept. 11, 2001.

The prosecutor, Clayton G. Trivett Jr., wrote to defense lawyers on Thursday “that an official in the Pentagon has just signed a memo approving the delivery of the Covid-19 vaccine to the detainee population in Guantánamo.”

Medical workers at the U.S. naval base began vaccinating the 6,000 residents on Jan. 8, including the 1,500 troops assigned to the detention operation. But the Trump administration had declined to say whether prisoners would be vaccinated.

The 40 detainees at the prison complex could start receiving the first of the two required doses of vaccine“on a voluntary basis” as soon as Monday, Mr. Trivett said. Under Pentagon policy, because the Food and Drug Administration has given only emergency-use authorization to the Moderna and Pfizer-BioNTech vaccines, the recipient’s consent is required to administer the shots.

It is not known how many people at Guantánamo have been infected with the coronavirus. Early in the pandemic, the military reported two cases there, both believed to be sailors. The Defense Department then halted disclosure of data about specific installations.

Lack of vaccinations has been a major obstacle to resuming war crimes hearings at the base’s Camp Justice compound. It was not immediately known whether the defendants in the Sept. 11 case, including Khalid Shaikh Mohammed, would consent to be vaccinated.

An Army judge has scheduled an arraignment on Feb. 22 for three prisoners accused of conspiring in deadly terrorist attacks in Indonesia in 2002 and 2003. Under the timeline described by Mr. Trivett, prisoners who agree to be vaccinated could receive their second dose on the eve of the arraignment, the first at Guantánamo’s war court since 2014.

The arraignment hearing would be the first court appearance for the three detainees — Encep Nurjaman, who is known as Hambali; Mohammed Nazir Bin Lep; and Mohammed Farik Bin Amin — who have been in U.S. custody since they were captured in Thailand in 2003.

Mr. Hambali, who is Indonesian, is held at Guantánamo as the former leader of Jemaah Islamiyah, a Southeast Asian extremist group that became an Al Qaeda affiliate before the Sept. 11 attacks. The other two men are Malaysians accused of being Mr. Hambali’s accomplices in the 2002 nightclub bombings in Bali, which killed 202 people, and the 2003 Marriott hotel bombing in Jakarta, which killed at least 11 people and wounded at least 80.

Lawyers for several of the detainees said they would need to consult with their clients by letter about whether to consent to be vaccinated.

Dr. Terry Adirim, the Pentagon’s principal deputy assistant secretary of defense for health affairs, signed the memo authorizing the vaccination of the detainees on Wednesday, said Mike Howard, a Pentagon spokesman.

Video

transcript

Back

transcript

Pentagon Asked to Aid Vaccine Rollout

The Defense Department said it would fulfill a Federal Emergency Management Agency request for help running coronavirus vaccination sites as much as it can.

We are in receipt of a request by FEMA for Defense Department capabilities to assist in vaccine distribution. I’m not able right now to go into great detail into what that request is. It is going through, just like we would get from a combatant command. It’s going through the same process. And it just came in yesterday, actually in the evening. And so it is being analyzed for resourcing and risk by the services. We’re obviously going to source this request. I mean, the secretary has made it very clear that we are going to provide as much capability and capacity as the Defense Department can afford to do to help with this national priority. We also have other jobs to do, clearly, in defense of the country. And so there’s risk whenever you pull capabilities away. And we’re going to have to balance that risk with this request. But we’re going to contribute. And we’re going to, and we’re going to do so in as aggressive a manner as we can.

Video player loadingThe Defense Department said it would fulfill a Federal Emergency Management Agency request for help running coronavirus vaccination sites as much as it can.CreditCredit…Jason Redmond/Agence France-Presse — Getty Images

The Pentagon is considering sending active duty troops to large-scale, federally run coronavirus vaccine centers, a major departure for the Department of Defense and the first significant sign that the Biden administration is moving to take more control of a program that states are struggling to manage.

The Federal Emergency Management Agency is hoping to set up roughly 100 vaccine sites nationwide as early as next month, and on Wednesday night requested that the Pentagon support the effort. The sites, and use of the military within them, would require the approval of state governments.

While many governors have turned to their National Guard units to assist with the mass effort to vaccinate Americans and outrace more contagious variants of the coronavirus, the Pentagon’s role has been largely behind the scenes, providing help with logistics.

Using active duty troops for vaccine distribution would demonstrate that the administration’s desire is to take a far bigger role in a task that states are struggling to expedite.

During his confirmation hearings last week, Lloyd J. Austin III, the secretary of defense, said that he would increase military support to help manage the pandemic. On Thursday, Max Rose, Mr. Austin’s senior adviser for Covid-19, said that his first topic of conversation in meetings with senior leaders had been on the topic, establishing that this is Mr. Austin’s number one priority.

Sending troops to help set up sites, assist with logistics and even put shots in arms is something the department is “actively considering,” Mr. Rose said. He declined to provide specific details, saying that Pentagon officials would be reviewing the request from FEMA carefully.

Many states and territories have already set up large vaccination sites, and more than half are using National Guard members to give shots, drawing on doctors, nurses, medics and others skilled in injections. FEMA, an agency within the federal Department of Homeland Security, has already told six states and Washington that it would spend $1 billion on vaccine sites.

It was not immediately clear where the vaccines would come from for new federal sites; they would most likely be supplied by the vaccine supply already given to individual states and territories, most of which have not come close to administering the vaccine they have been given.

Categories
Health

Novavax’s Vaccine Works Properly — Besides on Variant First Present in South Africa

“This is really worrying,” said Dr. Peter Hotez, vaccine expert at Baylor College of Medicine and inventor of a coronavirus vaccine. “We need to vaccinate the American people by late spring or early summer to prevent the South African and British variants from adopting.”

Drug manufacturers could update their vaccines and offer new ones on a regular basis, similar to the flu vaccine.

Covid19 vaccinations>

Answers to your vaccine questions

Am I eligible for the Covid vaccine in my state?

Currently more than 150 million people – almost half of the population – can be vaccinated. But each state makes the final decision on who goes first. The country’s 21 million healthcare workers and three million long-term care residents were the first to qualify. In mid-January, federal officials asked all states to open eligibility to anyone over the age of 65 and adults of any age with medical conditions that are at high risk of becoming seriously ill or dying of Covid-19. Adults in the general population are at the end of the line. If federal and state health authorities can remove bottlenecks in the distribution of vaccines, everyone over the age of 16 is eligible as early as spring or early summer. The vaccine has not been approved in children, although studies are ongoing. It can take months before a vaccine is available to anyone under the age of 16. For the latest information on vaccination guidelines in your area, see your state health website

Is the Vaccine Free?

You shouldn’t have to pay anything out of pocket to get the vaccine, despite being asked for insurance information. If you don’t have insurance, you should still get the vaccine for free. Congress passed law this spring banning insurers from applying cost-sharing such as a co-payment or deductible. It consisted of additional safeguards prohibiting pharmacies, doctors, and hospitals from charging patients, including uninsured patients. Even so, health experts fear that patients will end up in loopholes that make them prone to surprise bills. This could be the case for people who are charged a doctor’s visit fee with their vaccine or for Americans who have certain types of health insurance that are not covered by the new regulations. If you received your vaccine from a doctor’s office or emergency clinic, talk to them about possible hidden costs. To make sure you don’t get a surprise invoice, it is best to get your vaccine at a Department of Health vaccination center or local pharmacy as soon as the shots become more widely available.

Can I choose which vaccine to get?How long does the vaccine last? Do I need another next year?

That is to be determined. It is possible that Covid-19 vaccinations will become an annual event just like the flu vaccination. Or the vaccine may last longer than a year. We’ll have to wait and see how durable the protection from the vaccines is. To determine this, researchers will track down vaccinated people to look for “breakthrough cases” – those people who get Covid-19 despite being vaccinated. This is a sign of a weakening of protection and gives researchers an indication of how long the vaccine will last. They will also monitor the levels of antibodies and T cells in the blood of people who have been vaccinated to see if and when a booster shot might be needed. It is conceivable that people might need boosters every few months, once a year, or just every few years. It’s just a matter of waiting for the data.

Does my employer need vaccinations?Where can I find out more?

“This virus is throwing us curve balls every day. I think we just need to be prepared and realize that the first generation of vaccines may need to be updated,” said Dr. Jesse L. Goodman, professor of medicine and infectious diseases medicine at Georgetown University.

The Novavax study in the UK tested how many volunteers developed symptoms of Covid-19 a week after receiving a second dose. The company said Thursday that its initial analysis found that of 62 participants who got the disease, 56 had received a placebo and 6 had received the vaccine. According to Novavax, the newer, more contagious variant, first identified in the UK, caused about 50 percent of the cases in the study.

If these results were reflected in the larger clinical trial in the United States and Mexico, which involved approximately 16,000 out of 30,000 people, it would equate the vaccine with the Moderna and Pfizer-BioNTech vaccines, which were shown to be about 95 percent are effective.

But the news in South Africa was not that encouraging. Novavax’s smaller study found the vaccine to have an overall effectiveness of 49.4 percent. (The company reported that about 6 percent of the study participants were HIV positive, and for those who weren’t HIV positive, the vaccine had an effectiveness of 60 percent.) The company said the study was conducted from September through September The recording of cases of Covid-19 began midway through this month when the more contagious variant was widespread. According to Novavax, 44 study participants developed Covid-19 and sequenced the genetic lineage of 27 cases. Of these, 25 cases were caused by the more contagious version of the virus.

The company also said that about a third of study participants in South Africa had previously developed Covid-19 after being infected with the original form of the virus, and that their results showed that these previous infections did not protect them from the new variant. The company said its vaccine offered some protection for those who had previously contracted the disease, but did not include that group in its analysis.

Categories
World News

EU calls for vaccine makers ‘ship’ provides

Employee Jessica Mueller brings the Pfizer BioNTech Covid-19 coronavirus vaccine into a freezer in the vaccine warehouse, where the cans will be stored in Irxleben near Magdeburg, eastern Germany, before being distributed on January 8, 2021.

RONNY HARTMANN | AFP | Getty Images

LONDON – European Commission President Ursula von der Leyen on Tuesday called on coronavirus vaccine makers to deliver on their pledges to deliver millions of doses to the block and beyond.

Your comments face an unprecedented challenge for the EU when it comes to introducing vaccines in each of the 27 Member States. The EU’s vaccination campaign began on December 27, a later start than the UK or US, and the patchy, slow rollouts in many of its members have worried officials and the public.

“Europe has invested billions to support the development of the world’s first Covid-19 vaccines. To create a truly global common good,” said von der Leyen at the virtual Davos Agenda summit. “And now companies have to deliver. They have to meet their obligations.”

“Europe is determined to contribute to this global common good, but it also means business,” she said

“We were turned inwards”

A few hours later and at the same time, Chancellor Angela Merkel called for more cooperation and multilateralism in the life-saving blows.

She told the World Economic Forum: “It has become even clearer to me than before that we have to take a multilateral approach, that a self-isolating approach will not solve our problems.”

The coronavirus pandemic highlighted the high level of interdependence and networking in the world, and Germany initially made the mistake of looking inward to defeat the pandemic instead of working with others.

“We looked inward and cut ourselves off from each other, but very quickly we learned the lesson (not to do that),” she said.

Lack of vaccine

With the increase in infections and related bans, the EU is now faced with the challenge of vaccine shortages. Both Pfizer-BioNTech and AstraZeneca have warned of production issues that will either mean a temporary cut in production and the supplies the EU is receiving, and in the case of AstraZeneca, could mean it cannot meet a commitment to deliver 80 million Cans until the end of March.

An unnamed official told Reuters last week that AstraZeneca announced that the supply would instead be around 31 million doses, around 60% less than envisaged by the EU, which is expected to use the vaccine for emergencies later this week.

The news, understandably, enraged the bloc, which threatened to restrict exports of vaccines from the EU. The Pfizer BioNTech vaccine is made in Belgium.

Talks between the EU and AstraZeneca are due to resume on Wednesday. The former asked the pharmaceutical company to provide detailed plans for the manufacture and sale of vaccines. EU Health Commissioner Stella Kyriakides said in a statement on Monday that an “export transparency mechanism” would be put in place to assess vaccine exports from the EU.

Haves vs. have-nots

The supply of vaccines is also a hot topic of conversation outside of Europe, which like other wealthy nations has at least started its vaccination campaigns. The poorer countries say they are at the bottom when it comes to access to life-saving footage.

Last week, the World Health Organization head said the equitable distribution of coronavirus vaccines was at “serious risk” and warned of “catastrophic moral failure” if vaccines were not distributed fairly.

This point was repeated on Tuesday by Angel Gurria, Secretary General of the Organization for Economic Co-operation and Development.

“This is the biggest test for all of humanity, and especially for OECD countries, as most of those countries bought three, five or even ten times as many vaccines as their entire population,” Gurria told CNBC’s “Squawk Box Europe “. “”

These vaccines are “badly needed” in developing countries and could “be a very important source of overseas aid support and international cooperation,” he added. “We won’t get rid of this pandemic until it’s gone everywhere,” he said.

Categories
Health

In Israel, Infections Drop Sharply After One Shot of Vaccine

JERUSALEM – Israel, das weltweit führend bei der Impfung seiner Bevölkerung gegen das Coronavirus ist, hat einige ermutigende Neuigkeiten hervorgebracht: Frühe Ergebnisse zeigen einen signifikanten Rückgang der Infektion nach nur einem Schuss eines Impfstoffs mit zwei Dosen und bessere Ergebnisse als erwartet nach beiden Dosen.

Experten des öffentlichen Gesundheitswesens warnen davor, dass die auf dem Pfizer-BioNTech-Impfstoff basierenden Daten vorläufig sind und keinen klinischen Studien unterzogen wurden. Trotzdem bezeichnete Dr. Anat Ekka Zohar, Vizepräsident von Maccabi Health Services, einer der israelischen Organisationen zur Erhaltung der Gesundheit, die die Daten veröffentlicht haben, sie als „sehr ermutigend“.

Im ersten frühen Bericht verglich Clalit, Israels größter Gesundheitsfonds, 200.000 Menschen ab 60 Jahren, die eine erste Dosis des Impfstoffs erhalten hatten, mit einer entsprechenden Gruppe von 200.000, die noch nicht geimpft worden waren. Es hieß, dass die teilweise geimpften Patienten 14 bis 18 Tage nach ihren Schüssen mit einer um 33 Prozent geringeren Wahrscheinlichkeit infiziert waren.

Etwa zur gleichen Zeit gab Maccabis Forschungsabteilung an, nach nur einer Dosis einen noch größeren Rückgang der Infektionen festgestellt zu haben: eine Abnahme von etwa 60 Prozent, 13 bis 21 Tage nach dem ersten Schuss, bei den ersten 430.000 Personen, die ihn erhielten.

Maccabi gab keine Altersgruppe an oder gab an, ob die Daten mit einer übereinstimmenden, nicht geimpften Kohorte verglichen wurden.

Am Montag veröffentlichten das israelische Gesundheitsministerium und Maccabi neue Daten zu Personen, die beide Dosen des Impfstoffs erhalten hatten, und zeigten extrem hohe Wirksamkeitsraten.

Das Ministerium stellte fest, dass von 428.000 Israelis, die ihre zweite Dosis erhalten hatten, eine Woche später nur 63 oder 0,014 Prozent an dem Virus erkrankt waren. In ähnlicher Weise zeigten die Maccabi-Daten, dass mehr als eine Woche nach Erhalt der zweiten Dosis nur 20 von ungefähr 128.600 Menschen, etwa 0,01 Prozent, an dem Virus erkrankt waren.

In klinischen Studien erwies sich der Pfizer-Impfstoff nach zwei Dosen als zu 95 Prozent wirksam bei der Verhinderung einer Coronavirus-Infektion bei Menschen ohne Anzeichen einer vorherigen Infektion. Die israelischen Ergebnisse deuten darauf hin, dass die Wirksamkeit sogar noch höher sein könnte, obwohl strenge Vergleiche mit nicht geimpften Menschen noch nicht veröffentlicht wurden.

“Dies sind sehr ermutigende Daten”, sagte Dr. Zohar. “Wir werden diese Patienten genau überwachen, um zu untersuchen, ob sie weiterhin nur an leichten Symptomen leiden und keine Komplikationen infolge des Virus entwickeln.”

Sowohl Clalit als auch Maccabi warnten davor, dass ihre Ergebnisse vorläufig seien, und sagten, dass ihnen bald eine eingehendere statistische Analyse in von Experten begutachteten wissenschaftlichen Veröffentlichungen folgen werde.

Israel, wo mehr als 40 Prozent der Bevölkerung bereits eine erste Dosis des Impfstoffs erhalten haben, ist zu einem internationalen Testfall für die Wirksamkeit der Impfung geworden.

Mit seiner geringen Bevölkerungszahl, dem hochdigitalisierten universellen Gesundheitssystem und der schnellen Einführung militärisch unterstützter Impfstoffe bieten Israels reale Daten eine nützliche Ergänzung zu klinischen Studien für Forscher, Pharmaunternehmen und politische Entscheidungsträger.

Israel hat mit Pfizer einen Vertrag abgeschlossen, bei dem das Pharmaunternehmen dem Land eine frühzeitige und stetige Versorgung mit Impfstoffen im Austausch gegen Daten sicherstellte. Das Gesundheitsministerium hat eine redigierte Fassung der Vereinbarung veröffentlicht.

Trotz seines Wettlaufs um die Impfung leidet Israel unter einer verheerenden dritten Welle des Coronavirus. Die Regierung hat diesen Monat nach wochenlangen Infektionen und Todesfällen eine strikte nationale Sperre verhängt.

Israel sollte die meisten Flugreisen innerhalb und außerhalb des Landes ab Mitternacht am Montag einstellen, um die Ankunft neu auftretender Virusvarianten zu blockieren, die die Impfkampagne des Landes gefährden könnten. Zwei Impfstoffhersteller sagten am Montag, dass ihre Impfstoffe gegen eine der neuen Varianten etwas weniger wirksam seien.

Solche realen Daten aus Israel sind zwar nützlich, unterliegen jedoch Variablen, die die Ergebnisse verzerren können und die durch klinische Studien berücksichtigt werden sollen.

Covid19 Impfungen >

Antworten auf Ihre Impfstofffragen

Wenn ich in den USA lebe, wann kann ich den Impfstoff bekommen?

Während die genaue Reihenfolge der Impfstoffempfänger von Staat zu Staat unterschiedlich sein kann, werden die meisten Ärzte und Bewohner von Langzeitpflegeeinrichtungen an erster Stelle stehen. Wenn Sie verstehen möchten, wie diese Entscheidung getroffen wird, hilft dieser Artikel.

Wann kann ich nach der Impfung wieder zum normalen Leben zurückkehren?

Das Leben wird erst wieder normal, wenn die Gesellschaft als Ganzes ausreichend Schutz gegen das Coronavirus erhält. Sobald die Länder einen Impfstoff zugelassen haben, können sie in den ersten Monaten höchstens einige Prozent ihrer Bürger impfen. Die nicht geimpfte Mehrheit bleibt weiterhin anfällig für Infektionen. Eine wachsende Anzahl von Coronavirus-Impfstoffen zeigt einen robusten Schutz vor Krankheit. Es ist aber auch möglich, dass Menschen das Virus verbreiten, ohne zu wissen, dass sie infiziert sind, weil sie nur leichte oder gar keine Symptome haben. Wissenschaftler wissen noch nicht, ob die Impfstoffe auch die Übertragung des Coronavirus blockieren. Selbst geimpfte Menschen müssen vorerst Masken tragen, Menschenmassen in Innenräumen meiden und so weiter. Sobald genügend Menschen geimpft sind, wird es für das Coronavirus sehr schwierig, gefährdete Personen zu finden, die infiziert werden können. Je nachdem, wie schnell wir als Gesellschaft dieses Ziel erreichen, könnte sich das Leben im Herbst 2021 einem normalen Zustand nähern.

Muss ich nach der Impfung noch eine Maske tragen?

Ja, aber nicht für immer. Die beiden Impfstoffe, die möglicherweise in diesem Monat zugelassen werden, schützen die Menschen eindeutig vor einer Krankheit mit Covid-19. Die klinischen Studien, die diese Ergebnisse lieferten, waren jedoch nicht darauf ausgelegt, festzustellen, ob geimpfte Personen das Coronavirus noch verbreiten können, ohne Symptome zu entwickeln. Das bleibt eine Möglichkeit. Wir wissen, dass Menschen, die von Natur aus mit dem Coronavirus infiziert sind, es verbreiten können, ohne Husten oder andere Symptome zu haben. Die Forscher werden diese Frage bei der Einführung der Impfstoffe intensiv untersuchen. In der Zwischenzeit müssen sich selbst geimpfte Menschen als mögliche Spreizer vorstellen.

Wird es wehtun? Was sind die Nebenwirkungen?

Der Impfstoff gegen Pfizer und BioNTech wird wie andere typische Impfstoffe als Schuss in den Arm abgegeben. Die Injektion unterscheidet sich nicht von denen, die Sie zuvor erhalten haben. Zehntausende Menschen haben die Impfstoffe bereits erhalten, und keiner von ihnen hat ernsthafte gesundheitliche Probleme gemeldet. Einige von ihnen haben jedoch kurzlebige Beschwerden verspürt, darunter Schmerzen und grippeähnliche Symptome, die normalerweise einen Tag anhalten. Es ist möglich, dass die Leute planen müssen, nach dem zweiten Schuss einen Tag frei zu nehmen oder zur Schule zu gehen. Obwohl diese Erfahrungen nicht angenehm sind, sind sie ein gutes Zeichen: Sie sind das Ergebnis der Begegnung Ihres eigenen Immunsystems mit dem Impfstoff und einer starken Reaktion, die eine dauerhafte Immunität gewährleistet.

Werden mRNA-Impfstoffe meine Gene verändern?

Nein. Die Impfstoffe von Moderna und Pfizer verwenden ein genetisches Molekül, um das Immunsystem zu stärken. Dieses als mRNA bekannte Molekül wird schließlich vom Körper zerstört. Die mRNA ist in einer öligen Blase verpackt, die mit einer Zelle verschmelzen kann, so dass das Molekül hineinrutschen kann. Die Zelle verwendet die mRNA, um Proteine ​​aus dem Coronavirus herzustellen, die das Immunsystem stimulieren können. Zu jedem Zeitpunkt kann jede unserer Zellen Hunderttausende von mRNA-Molekülen enthalten, die sie produzieren, um eigene Proteine ​​herzustellen. Sobald diese Proteine ​​hergestellt sind, zerkleinern unsere Zellen die mRNA mit speziellen Enzymen. Die mRNA-Moleküle, die unsere Zellen herstellen, können nur wenige Minuten überleben. Die mRNA in Impfstoffen ist so konstruiert, dass sie den Enzymen der Zelle etwas länger standhält, sodass die Zellen zusätzliche Virusproteine ​​bilden und eine stärkere Immunantwort auslösen können. Die mRNA kann jedoch höchstens einige Tage halten, bevor sie zerstört wird.

Die frühen israelischen Zahlen basieren auf den ersten Personen, die den Impfstoff erhalten haben. Solche Leute, sagen Experten, sind wahrscheinlich besorgter oder über das Virus informiert und daher vorsichtiger in Bezug auf soziale Distanzierung und das Tragen von Masken. Sie könnten sich auch von denen unterscheiden, die sich nicht beeilten, den Standort und den sozioökonomischen Status zu bestimmen.

Experten sagen auch, dass sich die Krankheit im Laufe der Zeit ändert. Prof. Ran Balicer, Chief Innovation Officer bei Clalit und führender israelischer Epidemiologe, sagte, dass zwei Wochen alte Daten wie Beweise aus einer anderen Zeit oder “in israelischer Hinsicht vor etwa einer Million Impfstoffen” sein können.

Maccabi sagte, dass es wöchentlich mehr Daten veröffentlichen würde. “Die Hauptbotschaft”, sagte Maccabi in einer Erklärung, ist, dass bereits die erste Dosis des Impfstoffs “wirksam ist und die Morbidität verringert und Krankenhausaufenthalte um viele zehn Prozent senkt.”

Experten weisen darauf hin, dass die Veröffentlichung von Rohdaten die Gefahr birgt, dass sie falsch interpretiert werden.

Nachdem Clalit vor zwei Wochen erstmals seine frühen Zahlen veröffentlicht hatte, hörten viele Menschen von einem Rückgang der Fälle um 33 Prozent, nicht von den erwarteten 95 Prozent, und kamen zu dem falschen Schluss, dass der Pfizer-Schuss nicht funktionierte.

In Großbritannien gab es einen Aufruhr, bei dem die Behörden die Abgabe der zweiten Dosis um bis zu 12 Wochen verzögert haben, im Gegensatz zu der 21-tägigen Lücke, auf die Pfizer seine Versuche stützte.

Professor Balicer betrachtete die Ergebnisse als gute Nachricht und war bestürzt darüber, wie sie interpretiert wurden.

“Wir waren beruhigt genug, um allen zu sagen, dass wir sehen, was wir gleich nach Tag 14 sehen sollten”, sagte er. “Ich weiß nicht, wie es zu einer Botschaft von ‘Oh mein Gott, es funktioniert nicht’ wurde.”

Professor Balicer, der auch Vorsitzender des Expertenteams ist, das die israelische Regierung bei ihrer Reaktion auf Covid-19 berät, hoffte, dass die positiven Ergebnisse einen Einfluss auf eine bevorstehende Regierungsentscheidung bezüglich einer dritten Sperrung haben könnten.

“Covid hat uns alle zu Amateurwissenschaftlern gemacht”, sagte Talya Miron-Shatz, außerordentliche Professorin und Expertin für medizinische Entscheidungsfindung am Ono Academic College in Zentralisrael. “Wir alle betrachten Daten, aber die meisten Menschen sind keine Wissenschaftler.”

Israel, das am 20. Dezember mit der Impfung von Menschen begann, hat mehr als 2,6 Millionen Israelis einen ersten Schuss gegeben und beide Schüsse mehr als einer Million Menschen.

Nachdem Israel mit Menschen ab 60 Jahren, Beschäftigten im Gesundheitswesen und anderen gefährdeten Personen begonnen hat, bietet es jetzt Impfungen für Menschen über 40 und Schüler im Alter von 16 bis 18 Jahren an, damit sie wieder zur Schule gehen können. Das Militär unterstützt die Bemühungen und 700 Reservemediziner der Armee helfen in Impfzentren.

Prof. Jonathan Halevy, der Präsident des Shaare Zedek Medical Center in Jerusalem, hatte die Ergebnisse der HMOs nicht untersucht, sagte jedoch, dass er zwei Wochen nach Einführung der ersten Dosis in schweren Fällen einen Rückgang bemerkte.

“Ich kenne mehrere Leute, die sich kurz vor dem Impfstoff infiziert haben, aber sie haben ihn leicht bekommen”, sagte er.

Dennoch bleibt Israel unter einer nationalen Sperre und die Beamten sind besorgt über die Entstehung neuer, hoch ansteckender Varianten. Es bleibt abzuwarten, wie wirksam die Impfstoffe gegen die neuen Varianten sind.

Trotz des scheinbar frühen Erfolgs des Impfstoffs richtet das Virus in Israel weiterhin Chaos an. Professor Halevy sagte, die Covid-Stationen seines Krankenhauses seien immer noch voll und er rechne damit, dass es weitere zwei oder drei Wochen dauern würde, bis ein Rückgang zu verzeichnen sei.

Das Virus hat allein in diesem Monat mehr als 1.000 Israelis getötet, fast ein Viertel derjenigen, die insgesamt an dem Pandemievirus gestorben sind.

Gesundheitsbeamte und Experten haben einen Großteil des jüngsten Anstiegs der Infektion auf die sich schnell ausbreitende Variante zurückgeführt, die erstmals in Großbritannien entdeckt wurde.

Categories
Business

Moderna Says Vaccine Nonetheless Protects In opposition to Virus Variants

Moderna’s vaccine is effective against new variants of the coronavirus that have emerged in the UK and South Africa, the company said on Monday. However, it appears to be less protective against the variant discovered in South Africa, so the company is developing a new form of the vaccine that could be used as a booster shot against this virus.

“We’re doing it today to be ahead of the curve if we have to,” said Dr. Tal Zaks, Chief Medical Officer of Moderna, in an interview. “I consider it an insurance policy.”

He added, “I don’t know if we need it and I hope we don’t.”

Moderna reported results from a study using blood samples from eight people who had received two doses of the vaccine and two monkeys who had also been immunized.

The British variant did not affect the amount of neutralizing antibodies – the type that can deactivate the virus – produced after vaccination. But with the South African form there was a six-fold decrease in those levels.

Even so, the company said, these antibodies remain “above levels expected to be protective”.

Moderna collaborated on the study with the Vaccine Research Center of the National Institute for Allergies and Infectious Diseases, which is part of the National Institutes of Health.

The results have not yet been published or peer-reviewed but have been submitted to bioRxiv, which publishes preliminary studies online.

The company’s action is part of a race to fight a changing virus that has already wreaked havoc around the world and is now threatening to mutate in ways that make the fight even more difficult.

Several new variants of the virus have emerged, with mutations that are worrying scientists. A form first discovered in the UK is about twice as contagious as the virus identified in China a year ago, and researchers have begun to suspect it could be more deadly too.

Other variants with different mutations have emerged in South Africa and Brazil, and preliminary laboratory studies suggested that these forms may have some level of resistance to the immunity that people develop after recovering from infection or with Moderna or Pfizer-BioNTech vaccinated were vaccinated.

The British variant has been found in at least 20 states, but the Brazilian and South African versions were not discovered in the United States.

Dr. Zaks said the new version of the Moderna vaccine, which targets the South African variant, could be used as a booster if needed a year after receiving the original vaccine.

The need for such a booster can be determined by doing blood tests to measure antibody levels or by observing the population of vaccinated people to see if they will develop the new variant.

“We don’t have any data on the Brazilian variant yet,” said Dr. Zaks. “We expect it to come close to the South African, if at all. This is the one with the greatest overlap. New tribes will continue to emerge and we will continue to evaluate them. “

Noting that it took Moderna 42 days to make the original vaccine, he said the company could make a new vaccine, “hopefully a little faster this time, but not by much”.

Talks with regulators about what would be required to make a new version of the vaccine available to the public were just beginning.

“It’s early,” said Dr. Zaks.

This evolving story will be updated.

Categories
Business

Pfizer sending fewer Covid vaccine vials to account for additional doses

Dr. Scott Gottlieb, who sits on Pfizer’s board of directors, on Monday defended the company’s move to send fewer vials of its Covid-19 vaccine and count six doses per vial instead of five. This is the best way to ensure the extra dose is used.

When the company started shipping vaccine bottles last month, pharmacists found that they could often extract an extra dose from each vial, which on paper only held five doses. That discovery meant the United States could actually receive more doses of the vaccine than the $ 200 million the Department of Defense bought under its deal with Pfizer.

“The bottom line is that this is a very scarce resource. We have to make sure that every dose is used,” Gottlieb said Monday in CNBC’s “Squawk Box”. “The only way to do this is to market this as a six-dose vial and have the right equipment ready to extract that sixth dose, which is what Pfizer is actually doing.”

The New York Times reported Friday that Pfizer executives in recent weeks have successfully urged Food and Drug Administration officials to revise the wording of the vaccine’s emergency approval to officially include the sixth dose for the federal treaty.

Some pharmacists were confused by the extra doses or didn’t have the correct syringes to extract them and threw them away.

“During this pandemic that is killing many people around the world, it is important that we use all available vaccines and vaccinate as many people as possible. To keep an extra dose in each vial that could be used to vaccinate more people would be one Tragedy, “said company spokeswoman Amy Rose.

Gottlieb said Monday the move will help the US speed up the distribution of vaccine doses, adding that Pfizer can now deliver 120 million doses of the vaccine in the first quarter of 2021, up from 100 million before the labeling change.

However, the move puts pressure on U.S. pharmacists to extract six doses from each vial, which requires some special syringes called low dead space syringes. The US government, which ships kits of syringes and vaccine doses, has signed a contract with syringe manufacturers such as Becton Dickinson, the world’s largest syringe maker, to ensure supplies to local authorities.

However, Becton Dickinson is unable to significantly increase the US supply of syringes, Reuters reported earlier Monday, doubting how many vials the US can extract six doses from.

Gottlieb said the vaccines will only qualify as six-dose vials, which will also give local authorities the correct syringes to extract the final dose.

Gottlieb noted that when Pfizer applied for approval of his emergency vaccine, he knew that six doses could be taken from each vial, but revising the wording of the application would have delayed approval of the vaccine. The company therefore applied for approval with the intention of revising the wording later to reflect the six-dose vials.

He added that it took the U.S. FDA longer than regulators in other countries to make the change. Authorities in the UK, Switzerland and Israel have already revised the wording of their approvals for the Pfizer vaccine to take into account that each vial contains six doses.

Gottlieb, the former head of the FDA, clarified that the change should not be applied retrospectively, which means that all vials previously shipped will be counted as containing five doses.

But “at some point you had to set up the accommodation to properly account for the doses,” said Gottlieb.

Disclosure: Scott Gottlieb is a CNBC employee and a member of the boards of directors of Pfizer, genetic testing startup Tempus, health technology company Aetion Inc., and biotech company Illumina. He is also co-chair of the Healthy Sail Panel of Norwegian Cruise Line Holdings and Royal Caribbean.

Categories
Business

Authorities doesn’t understand how a lot Covid vaccine the U.S. has

WASHINGTON – The director of the Centers for Disease Control and Prevention warned Sunday that the federal government has no knowledge of how much coronavirus vaccine the nation has, a complication that adds to what was already a Herculean task before the Biden administration.

“I can’t tell you how much vaccine we have, and if I can’t tell you I can’t tell governors and I can’t tell state health officials,” said CDC director dr. Rochelle Walensky told Fox News Sunday.

“If they don’t know how much vaccine to get not just this week but next week and the week after, they can’t plan. They can’t figure out how many websites to launch, they can’t figure out.” how many vaccines they need and they can’t figure out how many appointments to make for the public, “Walensky said.

Speaking at an excavation at the Trump administration, Walensky said the lack of knowledge of vaccine supplies shows “the challenges that remain”.

Continue reading: Biden Surgeon General Pick Says US Race To Adapt Against New Strains Of Covid

President Joe Biden is committed to delivering 100 million Covid-19 vaccine shots within his first 100 days. The Biden government has been urged repeatedly whether this goal is ambitious enough given the severity of the pandemic.

Walensky admitted the US needs to vaccinate people faster, but said the nation is facing supply shortages. Production will increase after the first 100 days, Walensky said, and the expected launch of the Johnson & Johnson vaccine will also help resolve supply issues.

“We really hope that we have more vaccines and that we will increase the speed at which we can vaccinate,” said Walensky.

White House Chief of Staff Ron Klain said the nation is also facing distribution issues because the Trump administration, which launched the program, lacks a clear plan.

“The process of distributing the vaccine, especially outside of nursing homes and hospitals, to the entire community didn’t really exist when we got to the White House,” Klain told MSNBC’s Meet the Press on Sunday.

“So the process of getting this vaccine into your arms is the difficult process, we are lagging behind as a country and here we in the Biden administration are focused on getting this vaccine going,” he added .

The Chief Medical Officer of the White House, Dr. Anthony Fauci, who served in the Trump administration, said Sunday that Biden’s goal of 100 million doses in 100 days was not a final number.

“It’s really a floor, not a ceiling,” Fauci told CBS ‘Face The Nation. “It’s going to be a challenge. I think it was a sensible goal that was set. We always want to do better than the goal you set.”

Those 100 million injections will cover roughly 67 million people, Fauci said, some of whom received the two doses required while others received only one dose. To date, the US has given nearly 22 million doses, well below federal targets.

The need to vaccinate as many people as possible has received a new urgency as the coronavirus mutates. According to Fauci, the Covid-19 vaccines currently on the market may not be as effective against new strains.

Biden’s general surgeon emphasized on Sunday that the US was in a race to adapt to the new variants.

“The virus is basically telling us that it will keep changing and we need to be prepared for it,” said Dr. Vivek Murthy during an interview with ABC News’ This Week.

“So the bottom line is we’re in a race against these variants, the virus is going to change and it’s up to us to adapt and make sure we stay ahead,” said Murthy.

When asked if the US is in a race against time before a variant of Covid emerges that will make the vaccines ineffective, Walensky said Americans need to be vaccinated when they get the opportunity and stick to harm reduction strategies hold to deny the possibility of virus circulation.

“I would say we were in a race the whole time,” said Walensky. “The more viruses out there, the more viruses replicate, the more likely we are to have mutations and variants.”